Contributions
Abstract: P476
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 15 Immunology
Background: CD4+CD28null T cells are chronically activated cytotoxic T cells with the ability to migrate to inflammation sites and contribute to tissue damage.
Objective: We investigate whether CD4+CD28null T cells induce worse clinical outcomes in multiple sclerosis (MS) and evaluate the prognostic value of these cells.
Methods: CD4+CD28 null T cell percentages were measured in the blood of 176 MS patients with relapsing-remitting MS (=baseline). Multimodal evoked potentials (EP) combining information on motoric, visual and somatosensoric EP and expanded disability status scale (EDSS) were used as outcome measurements at baseline and after 3 and 5 years.
Results: Baseline CD4+CD28null T cell percentages are associated with EP (P=0.003), indicating a link between these cells and disease severity. In addition, baseline CD4+CD28null T cell percentage have a prognostic value since they are associated with EP after 3 years (P=0.005) and with EP and EDSS after 5 years (P=0.008 and P=0.003).
Conclusion: This study provides a direct link between CD4+CD28null T cell percentages and MS disease severity. Moreover, CD4+CD28null T cell percentage is a predictor for worse prognosis. Investigating strategies to block or reverse pathways in the formation of these cells could result in new treatments that slow down MS disease progression.
Disclosure:
LMP: nothing to disclosure,
MV: nothing to disclosure,
VS: nothing to disclosure,
BVW: nothing to disclosure,
PS: nothing to disclosure,
BB: nothing to disclosure,
NH: nothing to disclosure.
Abstract: P476
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 15 Immunology
Background: CD4+CD28null T cells are chronically activated cytotoxic T cells with the ability to migrate to inflammation sites and contribute to tissue damage.
Objective: We investigate whether CD4+CD28null T cells induce worse clinical outcomes in multiple sclerosis (MS) and evaluate the prognostic value of these cells.
Methods: CD4+CD28 null T cell percentages were measured in the blood of 176 MS patients with relapsing-remitting MS (=baseline). Multimodal evoked potentials (EP) combining information on motoric, visual and somatosensoric EP and expanded disability status scale (EDSS) were used as outcome measurements at baseline and after 3 and 5 years.
Results: Baseline CD4+CD28null T cell percentages are associated with EP (P=0.003), indicating a link between these cells and disease severity. In addition, baseline CD4+CD28null T cell percentage have a prognostic value since they are associated with EP after 3 years (P=0.005) and with EP and EDSS after 5 years (P=0.008 and P=0.003).
Conclusion: This study provides a direct link between CD4+CD28null T cell percentages and MS disease severity. Moreover, CD4+CD28null T cell percentage is a predictor for worse prognosis. Investigating strategies to block or reverse pathways in the formation of these cells could result in new treatments that slow down MS disease progression.
Disclosure:
LMP: nothing to disclosure,
MV: nothing to disclosure,
VS: nothing to disclosure,
BVW: nothing to disclosure,
PS: nothing to disclosure,
BB: nothing to disclosure,
NH: nothing to disclosure.